EUVIMEDEUVIMED entdecken
Crossref

1733-P: Effect of Mazdutide on Kidney Function in Adults with Obesity or Overweight

STANLEY HSIA, HAROLD E. BAYS, LIANA K. BILLINGS, ANN MARIE K. WEIDEMAN, OLIMPIA FERREIRA GALVAO DE ARAUJO, SIREL GURBUZ, TAMER COSKUN, AXEL HAUPT, MELISSA THOMAS, KIEREN J. MATHER

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1733-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von STANLEY HSIA und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Mazdutide (MAZ; LY3305677), a dual agonist of the GLP-1 and glucagon receptors, was previously shown to reduce body weight (up to 22.3% at 48 weeks) vs placebo (PBO), with mild-to-moderate gastrointestinal events as the most common TEAEs. We examined whether MAZ also improved measures of kidney function.

Methods

In this Phase 2 study (NCT06124807), adults (N=179) with BMI ≥30 kg/m², or BMI ≥27 kg/m² with weight-related comorbidities, excluding T2D, were randomly assigned to 48 weeks of once-weekly subcutaneous MAZ 3/6 mg (dose escalation at W32; n=32), 10 mg (n=48), 16 mg (n=51), or PBO (n=48). Changes from baseline (CFB) in selected kidney parameters were estimated using a mixed model for repeated measures (MMRM), presented as least squares means and standard errors (SE).

Results

At W32, cystatin C-derived eGFR increased significantly from baseline vs PBO with MAZ 10 mg (CFB [SE] in mL/min/1.73 m²: 7.7 [1.6]; p <0.001) and MAZ 16 mg (7.2 [2.1]; p=0.006), compared with -0.3 [1.6] for PBO. Urine albumin-to-creatinine ratio (UACR) decreased significantly from baseline vs PBO in all MAZ groups: -39.8% [10.8] for 3/6 mg (p=0.028), -36.2% [6.1] for 10 mg (p=0.007), -32.7% [7.7] for 16 mg (p=0.030), compared with -4.2% [11.1] for PBO at W32. The higher doses also achieved clinically relevant decreases in systolic blood pressure at W32 and W48.

Conclusion

Compared to placebo, MAZ improved eGFR and UACR, suggesting benefits in kidney function in adults with obesity/overweight without T2D. Disclosure S. Hsia: Research Support; Current; Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH. Research Support; Ended; Biomea Fusion, Inc. Research Support; Current; Corcept Therapeutics, Currax Pharmaceuticals. Research Support; Ended; Inventiva Pharma. Research Support; Current; Eli Lilly and Company, Novo Nordisk A/S, Regor Pharmaceuticals, Inc., Sparrow Pharmaceuticals, Viking Therapeutics, Zealand Pharma A/S. H.E. Bays: Research Support; Current; 89bio, Inc., Alon Medtech/Epitomee, Altimmune, Amgen Inc., AstraZeneca, Bioage, Boehringer Ingelheim International GmbH, Carmot Therapeutics, Inc., Eli Lilly and Company, Graviton, Merck & Co., Inc., Metsera, Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc., Regeneron Pharmaceuticals Inc., Birdrock, Tern, Viking Therapeutics, Vivus, Zomagen. Advisory Panel; Current; 89bio, Inc., Altimmune, Amgen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Regeneron Pharmaceuticals Inc., Rivus, Zomagen, zyversa. Research Support; Current; Kailera. Advisory Panel; Current; Merck & Co., Inc. L.K. Billings: Advisory Panel; Current; Novo Nordisk, Lilly, Sanofi, Amgen Inc., Bayer AG. A.K. Weideman: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. O. Ferreira Galvao de Araujo: Employee; Current; Eli Lilly and Company. S. Gurbuz: Employee; Current; Eli Lilly and Company. T. Coskun: Employee; Current; Eli Lilly and Company. A. Haupt: Employee; Ended; Lilly. Stock/Shareholder; Ended; Lilly. M. Thomas: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. K.J. Mather: Employee; Current; Eli Lilly and Company.

Zitieren

APA

HSIA, S., BAYS, H. E., BILLINGS, L. K., WEIDEMAN, A. M. K., ARAUJO, O. F. G. D., GURBUZ, S., COSKUN, T., HAUPT, A., THOMAS, M., & MATHER, K. J. (2026). 1733-P: Effect of Mazdutide on Kidney Function in Adults with Obesity or Overweight. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1733-p

Vancouver

HSIA S, BAYS HE, BILLINGS LK, WEIDEMAN AMK, ARAUJO OFGD, GURBUZ S, et al. 1733-P: Effect of Mazdutide on Kidney Function in Adults with Obesity or Overweight. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1733-p

BibTeX
@article{HSIA2026,
  author = {HSIA, STANLEY and BAYS, HAROLD E. and BILLINGS, LIANA K. and WEIDEMAN, ANN MARIE K. and ARAUJO, OLIMPIA FERREIRA GALVAO DE and GURBUZ, SIREL and COSKUN, TAMER and HAUPT, AXEL and THOMAS, MELISSA and MATHER, KIEREN J.},
  title = {1733-P: Effect of Mazdutide on Kidney Function in Adults with Obesity or Overweight},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1733-p}
}
Kostenlos starten →